Generic Drug Stems, Labs, and Supportive Care Patterns
Key Takeaways
- ONCC uses generic drug names only, so final review should emphasize generic names, suffix stems, mechanisms, and signature toxicity clusters.
- Drug stems aid recognition but do not replace knowing route, indication, monitoring, and patient-specific risk; some agents break the suffix rule.
- Lab review should focus on values that change nursing assessment, escalation, education, and treatment readiness — for example ANC under 500, platelets under 50,000, or rising creatinine.
- Supportive care items test prevention and early reporting of infection, bleeding, mucositis, neuropathy, nausea, diarrhea, constipation, and pain.
- Anthracycline lifetime cumulative dose (doxorubicin around 450-550 mg/m2) and taxane/platinum hypersensitivity are recurring high-yield safety facts.
Generic Drug Stems, Labs, and Supportive Care Patterns
Review generic names only
ONCC tests use generic drug names only. In final review, pull brand-only flashcards and rewrite them as generics. A brand name may help you recognize a drug at the bedside, but no exam stem depends on it. Build last-week pharmacology around five anchors per agent: class, mechanism clue, common route, signature toxicities, and the one urgent teaching point.
Do not try to learn dosing for every regimen. The exam rewards recognizing the class, the danger signal, and the nursing response — not reciting milligrams. The exceptions worth memorizing are a handful of safety thresholds, covered below.
High-yield generic name stems
| Stem | Class | Nursing review focus |
|---|---|---|
| -mab | Monoclonal antibody | Infusion reactions, immune-related adverse events, target-specific toxicity |
| -nib | Kinase inhibitor (oral) | Adherence, drug interactions, rash, diarrhea, hypertension, liver tests |
| -parib | PARP inhibitor | Cytopenias, fatigue, nausea, reproductive precautions |
| -zomib | Proteasome inhibitor | Peripheral neuropathy, thrombocytopenia, herpes reactivation (antiviral prophylaxis) |
| -ciclib | CDK4/6 inhibitor | Neutropenia, fatigue, diarrhea, agent-specific liver/QT monitoring |
| -platin | Platinum chemotherapy | Nausea, nephrotoxicity, ototoxicity, peripheral neuropathy, hypersensitivity |
| -taxel | Taxane | Hypersensitivity (premedicate), neuropathy, myelosuppression, alopecia |
| -rubicin | Anthracycline | Cardiotoxicity, vesicant, myelosuppression, lifetime cumulative dose limit |
Stems are clues, not guarantees — bortezomib (-zomib) and carfilzomib differ in cardiac risk, and not every -nib behaves identically. If a stem names a drug you only half-recognize, use the suffix to narrow the class, then return to the patient problem in the question.
Lab patterns and thresholds worth drilling
| Lab / pattern | Action threshold or meaning | Why it matters for OCN |
|---|---|---|
| Absolute neutrophil count (ANC) | Under 500 = severe neutropenia; under 1,000 and falling = high risk | Neutropenic precautions; fever is a sepsis emergency |
| Platelets | Under 50,000 = bleeding/procedure risk; under 10,000-20,000 = spontaneous bleed risk | Bleeding precautions, fall risk, transfusion readiness |
| Hemoglobin | Symptoms and trend drive action more than a single number | Fatigue, dyspnea, activity tolerance, transfusion assessment |
| Creatinine (rising) | Any acute rise on nephrotoxic therapy | Hydration, dose-readiness, TLS or AKI concern |
| Liver transaminases (rising) | 3-5x upper limit signals hepatotoxicity / immune hepatitis | Treatment readiness, hold/escalate per orders |
| Potassium (high) | Above ~5.0-5.5 with EKG change | TLS or AKI; cardiac monitoring |
| Calcium LOW + phosphate HIGH | Classic TLS chemistry | Telemetry, hydration, urgent escalation |
| Calcium HIGH | Above ~10.5 mg/dL corrected | Hypercalcemia of malignancy; hydration, fall risk |
Do not memorize labs as isolated numbers. The exam asks what the nurse should assess, teach, report, or prioritize. Always pair an abnormal value with symptoms and context: a potassium rise after high-burden leukemia therapy is an emergency; a stable chronic value already managed by the team is not.
Supportive care pattern table
| Problem | Assessment focus | Teaching focus |
|---|---|---|
| Nausea/vomiting | Intake, hydration, timing relative to therapy, antiemetic use | Take antiemetics as scheduled; call for uncontrolled symptoms |
| Diarrhea | Stools over baseline, blood, fever, dizziness | Hydrate; report severe/persistent diarrhea; no self-treatment on immunotherapy |
| Constipation | Opioids, intake, bowel pattern, obstruction signs | Bowel regimen as prescribed; call for severe pain or vomiting |
| Mucositis | Oral intake, pain, infection, bleeding | Bland oral care; avoid alcohol/spicy/acidic foods; report inability to drink or fever |
| Peripheral neuropathy | Falls, fine-motor change, pain, gait | Safety measures; report worsening before injury |
| Fatigue | Reversible causes (anemia, sleep, distress) | Energy conservation, balanced activity, report severe change |
| Pain | Location, quality, severity, function, side effects | Scheduled plus breakthrough use; prevent constipation; safe storage |
Final-week drug review method and traps
Write one line per agent: generic name, class stem, signature toxicity, urgent teaching point. Examples: paclitaxel — taxane — hypersensitivity and neuropathy — report dyspnea or chest tightness during infusion; doxorubicin — anthracycline — cardiotoxicity and vesicant — track lifetime cumulative dose (around 450-550 mg/m2) and report IV-site burning; pembrolizumab — checkpoint inhibitor — immune organ inflammation — report new diarrhea, cough, severe fatigue, rash, or jaundice early.
Common traps to refuse: telling a patient to wait out a neutropenic fever; normalizing new dyspnea on immunotherapy; instructing a patient to permanently stop oral therapy without contacting the team; recommending herbal supplements in place of evidence-based symptom care; or letting a familiar drug name distract you from the new safety problem in the stem.
Oral therapy adherence and growth factors
Oral anticancer agents now dominate targeted therapy, and the OCN reflects that shift with adherence and self-management items. Because the patient doses at home, teaching becomes the safety net: take the drug at the same time daily, do not double a missed dose without instruction, store away from children and heat, use gloves or avoid bare-hand splitting, and call the clinic for the specific toxicity thresholds (for example, several loose stools above baseline on a kinase inhibitor, or a new rash covering a large body area).
A patient who quietly skips doses to control diarrhea is a classic distractor scenario — the keyed answer assesses the reason and contacts the team, never simply praises the patient for stopping.
Supportive pharmacology rounds out the picture. Know that colony-stimulating factors (filgrastim, pegfilgrastim) support neutrophil recovery and reduce febrile-neutropenia risk but do not treat an active infection. Erythropoiesis-stimulating agents carry thrombosis and tumor-progression warnings, so they are used cautiously and not as a quick fatigue fix. Bone-modifying agents (zoledronic acid, denosumab) require dental evaluation because of osteonecrosis of the jaw risk and monitoring for hypocalcemia. Pairing each support drug with its single most-tested caution keeps these items fast and reliable.
Why should final OCN drug review emphasize generic names?
A drug ending in -parib most strongly suggests which review focus?
Which lab pattern is most consistent with tumor lysis syndrome?